Compare MAX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAX | PHAR |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.4M | 1.2B |
| IPO Year | 2020 | 2020 |
| Metric | MAX | PHAR |
|---|---|---|
| Price | $8.07 | $12.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.70 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 572.7K | 10.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $13.42 | $10.04 |
| Revenue Next Year | $8.16 | $2.51 |
| P/E Ratio | ★ $38.45 | $3,041.22 |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $9.54 |
| 52 Week High | $13.92 | $21.34 |
| Indicator | MAX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 31.36 |
| Support Level | $7.09 | $11.83 |
| Resistance Level | $10.26 | $17.29 |
| Average True Range (ATR) | 0.49 | 0.44 |
| MACD | -0.14 | -0.33 |
| Stochastic Oscillator | 4.67 | 22.05 |
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.